What question did this study set out to answer?

To determine whether value thresholds defined by incremental cost-effectiveness ratios differ between oncology drugs and pharmaceuticals in other therapeutic areas.

November 1, 2014Journal of Managed Care PharmacyOpen Access

Do Value Thresholds for Oncology Drugs Differ from Nononcology Drugs?

View Full Paper

Ask AI

Bookmark

Authors

YBYuna H. BaeUniversity of Southern California CMC. Daniel MullinsUniversity of Maryland, Baltimore

Discussion

Member takes

Implication

Systematic review reveals higher incremental cost-effectiveness ratios and value thresholds for cancer drugs than noncancer therapies, suggesting greater economic leniency for oncology treatments.

Key Points

To determine whether value thresholds defined by incremental cost-effectiveness ratios differ between oncology drugs and pharmaceuticals in other therapeutic areas.
Searched PubMed for United States studies published between January 2003 and December 2013 reporting incremental cost-effectiveness ratios (ICERs) using quality-adjusted life-years (QALYs) from a U.S. payer perspective.
Evaluated 54 eligible drug therapy articles (N=54), categorizing them into oncology therapeutics (n=13) and nononcology therapeutic areas (n=41) to analyze mean ICERs and value thresholds.
Oncology drug interventions showed a mean ICER of $138,582/QALY (median $55,500/QALY) compared with $49,913/QALY (median $31,000/QALY) for nononcology drugs.
ICERs fell below $50,000/QALY in 45.0% of cancer drugs versus 72.0% of noncancer drugs, and below $100,000/QALY in 70.0% versus 90.0%, respectively.
Explicitly cited willingness-to-pay thresholds ranged from $100,000 to $150,000/QALY for oncology drugs compared with traditional thresholds of $50,000 to $100,000/QALY for other therapeutic areas.

Cite This Study

Bae et al. (2014) studied this question.

synapsesocial.com/papers/6a82fb63292d2964071f2313 https://doi.org/10.18553/jmcp.2014.20.11.1086

View Full Paper

Ask AI

Bookmark

Implication

Systematic review reveals higher incremental cost-effectiveness ratios and value thresholds for cancer drugs than noncancer therapies, suggesting greater economic leniency for oncology treatments.

Do Value Thresholds for Oncology Drugs Differ from Nononcology Drugs?

Discussion

Member takes

Implication

Key Points

Cite This Study

Do Value Thresholds for Oncology Drugs Differ from Nononcology Drugs?

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider